Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
March 15, 2024 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,000 | -- | 110,688 | |
March 17, 2023 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 85,688 | |
May 15, 2018 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 100,000 | -- | 124,643 | |
May 30, 2017 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 21,786 | -- | 21,786 | |
February 2, 2016 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 152,500 | |
March 17, 2015 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 37,500 | -- | 112,500 | |
June 20, 2014 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,000 | $3.50 | 5,000 | |
June 20, 2014 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 40,000 | |
June 20, 2014 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 35,000 | -- | 75,000 | |
February 19, 2019 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | -- | 325,047 | |
May 15, 2018 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 305,047 | |
May 30, 2017 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 48,571 | -- | 48,571 | |
September 6, 2016 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,663 | -- | 316,213 | |
February 2, 2016 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 12,000 | $1.33 | 19,926 | |
February 2, 2016 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 50,000 | -- | 275,550 | |
March 17, 2015 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 50,000 | -- | 225,550 | |
June 20, 2014 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 50,000 | -- | 175,550 | |
February 11, 2014 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 40,000 | -- | 125,500 | |
May 6, 2013 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 80,000 | -- | 385,000 | |
June 15, 2012 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 36,250 | $2.15 | 305,000 | |
February 22, 2012 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 13,750 | -- | 268,750 | |
December 12, 2011 | CMO | Form 4 | Open market or private purchase of non-derivative or derivative security | 5,000 | $2.00 | 35,687 | |
March 23, 2011 | CMO | Form 4 | Conversion of derivative security | 2,500 | $2.40 | 30,687 | |
March 23, 2011 | CMO | Form 4 | Conversion of derivative security | 6 | -- | -- | |
February 25, 2011 | CMO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 70,000 | $2.49 | 255,000 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.